Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction.

Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Mino-Kenudson M, Giovannucci EL, Meyerhardt JA, Fuchs CS.

Am J Gastroenterol. 2010 Feb;105(2):420-33. doi: 10.1038/ajg.2009.578. Epub 2009 Oct 6.

2.

Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.

Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS.

Clin Cancer Res. 2009 Oct 15;15(20):6412-20. doi: 10.1158/1078-0432.CCR-09-1438. Epub 2009 Oct 13.

3.

Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers.

Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS.

J Clin Oncol. 2009 Sep 20;27(27):4591-8. doi: 10.1200/JCO.2009.22.8858. Epub 2009 Aug 24.

4.

Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.

Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K, Nosho K, Wang YE, Peng S, Bass AJ, Haigis KM, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S.

Mol Cancer. 2014 May 31;13:135. doi: 10.1186/1476-4598-13-135.

5.

Association between molecular subtypes of colorectal cancer and patient survival.

Phipps AI, Limburg PJ, Baron JA, Burnett-Hartman AN, Weisenberger DJ, Laird PW, Sinicrope FA, Rosty C, Buchanan DD, Potter JD, Newcomb PA.

Gastroenterology. 2015 Jan;148(1):77-87.e2. doi: 10.1053/j.gastro.2014.09.038. Epub 2014 Sep 30.

6.

Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.

Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S.

Clin Cancer Res. 2012 Sep 1;18(17):4753-63. doi: 10.1158/1078-0432.CCR-11-3210. Epub 2012 Jul 2.

7.

CDK8 expression in 470 colorectal cancers in relation to beta-catenin activation, other molecular alterations and patient survival.

Firestein R, Shima K, Nosho K, Irahara N, Baba Y, Bojarski E, Giovannucci EL, Hahn WC, Fuchs CS, Ogino S.

Int J Cancer. 2010 Jun 15;126(12):2863-73. doi: 10.1002/ijc.24908.

8.

Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.

Zlobec I, Bihl M, Foerster A, Rufle A, Lugli A.

J Pathol. 2011 Nov;225(3):336-43. doi: 10.1002/path.2879. Epub 2011 Jun 9.

PMID:
21660972
9.

TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers.

Shima K, Morikawa T, Yamauchi M, Kuchiba A, Imamura Y, Liao X, Meyerhardt JA, Fuchs CS, Ogino S.

PLoS One. 2011;6(9):e25062. doi: 10.1371/journal.pone.0025062. Epub 2011 Sep 20.

10.

Predictors of lymph node count in colorectal cancer resections: data from US nationwide prospective cohort studies.

Morikawa T, Tanaka N, Kuchiba A, Nosho K, Yamauchi M, Hornick JL, Swanson RS, Chan AT, Meyerhardt JA, Huttenhower C, Schrag D, Fuchs CS, Ogino S.

Arch Surg. 2012 Aug;147(8):715-23.

11.

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.

Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS.

Gut. 2009 Jan;58(1):90-6. doi: 10.1136/gut.2008.155473. Epub 2008 Oct 2.

12.

Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.

Lee S, Cho NY, Choi M, Yoo EJ, Kim JH, Kang GH.

Pathol Int. 2008 Feb;58(2):104-13. doi: 10.1111/j.1440-1827.2007.02197.x.

PMID:
18199160
13.

CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.

Lee S, Cho NY, Yoo EJ, Kim JH, Kang GH.

Arch Pathol Lab Med. 2008 Oct;132(10):1657-65. doi: 10.1043/1543-2165(2008)132[1657:CIMPIC]2.0.CO;2.

PMID:
18834226
14.

Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.

Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS.

J Pathol. 2006 Oct;210(2):147-54.

PMID:
16850502
15.

Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample.

Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ, Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S.

PLoS One. 2008;3(11):e3698. doi: 10.1371/journal.pone.0003698. Epub 2008 Nov 12.

16.

Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer.

Sanchez JA, Krumroy L, Plummer S, Aung P, Merkulova A, Skacel M, DeJulius KL, Manilich E, Church JM, Casey G, Kalady MF.

Br J Surg. 2009 Oct;96(10):1196-204. doi: 10.1002/bjs.6683.

PMID:
19787768
17.

Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location.

Bae JM, Kim JH, Cho NY, Kim TY, Kang GH.

Br J Cancer. 2013 Aug 20;109(4):1004-12. doi: 10.1038/bjc.2013.430. Epub 2013 Jul 30.

18.

Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level.

Rhee YY, Kim MJ, Bae JM, Koh JM, Cho NY, Juhnn YS, Kim D, Kang GH.

Ann Surg Oncol. 2012 Oct;19(11):3441-8. doi: 10.1245/s10434-012-2410-7. Epub 2012 May 23.

PMID:
22618722
19.

Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer.

Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2765-72. doi: 10.1158/1055-9965.EPI-09-0490. Epub 2009 Sep 29.

20.

Tumor TP53 expression status, body mass index and prognosis in colorectal cancer.

Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, Nishihara R, Sato K, Meyerhardt JA, Fuchs CS, Ogino S.

Int J Cancer. 2012 Sep 1;131(5):1169-78. doi: 10.1002/ijc.26495. Epub 2011 Nov 19.

Supplemental Content

Support Center